Upgrades/Downgrades
Updated: 28-Mar-24 16:30 ET
Upgrades | |||||
Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
MAG Silver | MAG | Scotiabank | Sector Perform » Sector Outperform | ||
Kimberly-Clark | KMB | Evercore ISI | In-line » Outperform | $133 » $150 | |
Lands' End | LE | Craig Hallum | Hold » Buy | $9 » $15 | |
Vornado Rlty Trust | VNO | Morgan Stanley | Underweight » Equal-Weight | $24 » $26 | |
U.S. Bancorp | USB | HSBC Securities | Hold » Buy | $47 » $53 | |
Millicom International Cellular | TIGO | JP Morgan | Neutral » Overweight | ||
Triumph Group | TGI | Wolfe Research | Peer Perform » Outperform | $18 | |
Public Storage | PSA | Raymond James | Mkt Perform » Strong Buy | $330 | |
PNC | PNC | HSBC Securities | Reduce » Hold | $141 » $155 | |
Omnicom | OMC | Exane BNP Paribas | Neutral » Outperform | $115 | |
Estee Lauder | EL | BofA Securities | Neutral » Buy | $170 | |
Allstate | ALL | HSBC Securities | Hold » Buy | $158 » $190 | |
|
|||||
Downgrades | |||||
Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
Construction Partners | ROAD | Sidoti | Buy » Neutral | $59 | |
Palantir Technologies | PLTR | Monness Crespi & Hardt | Neutral » Sell | $20 | |
WB | Goldman | Buy » Neutral | |||
Vista Energy | VIST | UBS | Buy » Neutral | $40 » $47 | |
Pebblebrook Hotel Trust | PEB | Compass Point | Buy » Neutral | $17 | |
Molina Healthcare | MOH | BofA Securities | Neutral » Underperform | $439 | |
Galapagos NV | GLPG | BofA Securities | Neutral » Underperform | $41 » $31 | |
Extra Space Storage | EXR | Raymond James | Strong Buy » Outperform | $160 | |
Bank of America | BAC | HSBC Securities | Buy » Hold | $38 » $39 | |
Albany Intl | AIN | BofA Securities | Neutral » Underperform | $105 » $95 | |
Apple | AAPL | DZ Bank | Buy » Hold | $180 | |
|
|||||
Coverage Initiated | |||||
Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
enGene Holdings | ENGN | UBS | Buy | $37 | |
Xeris Biopharma | XERS | Oppenheimer | Outperform | $5 | |
Veru | VERU | Raymond James | Outperform | $3 | |
TransMedics Group | TMDX | Piper Sandler | Overweight | $95 | |
TruBridge | TBRG | RBC Capital Mkts | Outperform | $13 | |
Scholar Rock | SRRK | Raymond James | Strong Buy | $30 | |
Solid Biosciences | SLDB | William Blair | Outperform | $40 | |
SI-BONE | SIBN | Piper Sandler | Overweight | $25 | |
Progress Software | PRGS | DA Davidson | Buy | $65 | |
Merus | MRUS | Truist | Buy | $69 | |
Jasper Therapeutics | JSPR | RBC Capital Mkts | Outperform | $70 | |
Immunovant Sciences | IMVT | Oppenheimer | Outperform | $50 | |
Grindr | GRND | TD Cowen | Buy | $12 | |
Global Net Lease | GNL | Truist | Hold | $7 | |
CyberArk | CYBR | BTIG Research | Buy | $317 | |
Bentley Systems | BSY | William Blair | Outperform | ||
Aquestive Therapeutics | AQST | Raymond James | Outperform | $7 | |
ADC Therapeutics | ADCT | Guggenheim | Buy | $11 | |
|
|||||
Coverage Resumed | |||||
Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
Amgen | AMGN | Raymond James | Mkt Perform | ||
|
|||||
Coverage Reiterated/Price Tgt Changed* | |||||
Company | Ticker | Brokerage Firm | Ratings Change | Price Target | |
Cintas | CTAS | BofA Securities | Buy | $700 » $790 | |
Cintas | CTAS | RBC Capital Mkts | Outperform | $675 » $725 | |
Cintas | CTAS | Deutsche Bank | Hold | $629 » $726 | |
Cintas | CTAS | UBS | Buy | $680 » $790 | |
Cintas | CTAS | Robert W. Baird | Outperform | $660 » $750 | |
Cintas | CTAS | Goldman | Buy | $673 » $765 | |
Robinhood Markets | HOOD | KeyBanc Capital Markets | Overweight | $15 » $22 | |
Cellebrite DI | CLBT | Needham | Buy | $13 » $13.50 | |
Tesla | TSLA | Deutsche Bank | Buy | $218 » $200 | |
Tesla | TSLA | Wedbush | Outperform | $315 » $300 | |
Kroger | KR | Telsey Advisory Group | Outperform | $60 » $62 | |
RH | RH | Telsey Advisory Group | Market Perform | $285 » $335 | |
UPS | UPS | TD Cowen | Hold | $147 » $140 | |
Korro Bio | KRRO | H.C. Wainwright | Buy | $100 » $115 | |
Chipotle Mexican Grill | CMG | BTIG Research | Buy | $2750 » $3250 | |
|
|||||
(a) Brokerage firm initiating coverage participated in underwriting the recent IPO. |
(b) Brokerage firm resumes coverage. |
(c) Brokerage firm participated in the secondary offering. |
* This list of reiterations/target changes is not comprehensive. |